NVNO vs. BWAY, ARAY, CATX, PROF, SKIN, SGHT, KRMD, OBIO, LUCD, and INFU
Should you be buying enVVeno Medical stock or one of its competitors? The main competitors of enVVeno Medical include BrainsWay (BWAY), Accuray (ARAY), Perspective Therapeutics (CATX), Profound Medical (PROF), Beauty Health (SKIN), Sight Sciences (SGHT), KORU Medical Systems (KRMD), Orchestra BioMed (OBIO), Lucid Diagnostics (LUCD), and InfuSystem (INFU). These companies are all part of the "surgical & medical instruments" industry.
enVVeno Medical vs.
enVVeno Medical (NASDAQ:NVNO) and BrainsWay (NASDAQ:BWAY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, valuation, profitability and risk.
In the previous week, BrainsWay had 2 more articles in the media than enVVeno Medical. MarketBeat recorded 2 mentions for BrainsWay and 0 mentions for enVVeno Medical. BrainsWay's average media sentiment score of 1.55 beat enVVeno Medical's score of 0.00 indicating that BrainsWay is being referred to more favorably in the news media.
enVVeno Medical has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, BrainsWay has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500.
BrainsWay has a consensus target price of $13.17, indicating a potential upside of 67.51%. Given BrainsWay's stronger consensus rating and higher possible upside, analysts plainly believe BrainsWay is more favorable than enVVeno Medical.
BrainsWay has higher revenue and earnings than enVVeno Medical. enVVeno Medical is trading at a lower price-to-earnings ratio than BrainsWay, indicating that it is currently the more affordable of the two stocks.
enVVeno Medical received 86 more outperform votes than BrainsWay when rated by MarketBeat users. However, 67.31% of users gave BrainsWay an outperform vote while only 62.65% of users gave enVVeno Medical an outperform vote.
34.7% of enVVeno Medical shares are owned by institutional investors. Comparatively, 30.1% of BrainsWay shares are owned by institutional investors. 16.0% of enVVeno Medical shares are owned by company insiders. Comparatively, 19.0% of BrainsWay shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
BrainsWay has a net margin of 3.88% compared to enVVeno Medical's net margin of 0.00%. BrainsWay's return on equity of 3.52% beat enVVeno Medical's return on equity.
Summary
BrainsWay beats enVVeno Medical on 15 of the 17 factors compared between the two stocks.
Get enVVeno Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVNO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
enVVeno Medical Competitors List
Related Companies and Tools
This page (NASDAQ:NVNO) was last updated on 4/22/2025 by MarketBeat.com Staff
Buy NVNO Stock Free NVNO Stock Alerts